Biogen Inc. reported its fourth-quarter and full-year 2024 financial results, surpassing Wall Street's expectations for both adjusted earnings per share (EPS) and revenue. For the fourth quarter, Biogen reported an adjusted EPS of $3.44, beating the consensus estimate of $3.42, and revenue of $2.45 billion, exceeding the expected $2.41 billion. The company's full-year revenue reached $9.7 billion, marking a 2% decline year-over-year, while GAAP diluted EPS grew by 40% to $11.18 and non-GAAP diluted EPS by 17% to $3.44. Despite the strong quarterly performance, Biogen's guidance for 2025 adjusted EPS, set between $15.25 and $16.25, fell short of the $16.16 estimate. The company anticipates a mid-single digit percentage decline in revenue for 2025, excluding currency impact, compared to the $9.43 billion estimate. Biogen's new drugs, including Leqembi for Alzheimer's, which generated $87 million in the quarter, and Skyclarys for Friedreich's ataxia, with sales of $102 million, are expected to help offset declines in multiple sclerosis product sales.